NASDAQ:BLFS - BioLife Solutions Stock Price, Forecast & News

BioLife Solutions trades on the NASDAQ under the ticker symbol "BLFS."

BioLife Solutions Inc (NASDAQ:BLFS) announced its earnings results on Tuesday, November, 12th. The medical equipment provider reported $0.01 earnings per share for the quarter, meeting the Thomson Reuters' consensus estimate of $0.01. The medical equipment provider had revenue of $6.60 million for the quarter, compared to the consensus estimate of $7.65 million. BioLife Solutions had a net margin of 46.77% and a return on equity of 5.37%. View BioLife Solutions' Earnings History.

BioLife Solutions is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for BioLife Solutions.

BioLife Solutions issued an update on its FY 2020 After-Hours earnings guidance on Monday, November, 25th. The company provided EPS guidance of for the period. The company issued revenue guidance of $$50-56 million, compared to the consensus revenue estimate of $$42.95 million.

5 Wall Street analysts have issued twelve-month price targets for BioLife Solutions' shares. Their forecasts range from $22.00 to $26.00. On average, they expect BioLife Solutions' share price to reach $23.80 in the next year. This suggests a possible upside of 46.8% from the stock's current price. View Analyst Price Targets for BioLife Solutions.

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BioLife Solutions in the last year. There are currently 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for BioLife Solutions.

Headlines about BLFS stock have been trending positive recently, according to InfoTrie Sentiment Analysis. InfoTrie identifies positive and negative press coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. BioLife Solutions earned a news sentiment score of 3.0 on InfoTrie's scale. They also assigned news coverage about the medical equipment provider a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the stock's share price in the immediate future. View News Stories for BioLife Solutions.

BioLife Solutions saw a drop in short interest in December. As of December 31st, there was short interest totalling 1,620,000 shares, a drop of 5.8% from the December 15th total of 1,720,000 shares. Based on an average daily trading volume, of 144,600 shares, the days-to-cover ratio is currently 11.2 days. Approximately 10.7% of the shares of the stock are sold short. View BioLife Solutions' Current Options Chain.

Some companies that are related to BioLife Solutions include Natus Medical (NTUS), AxoGen (AXGN), Cutera (CUTR), TransMedics Group (TMDX), Zynex (ZYXI), Stereotaxis (STXS), Semler Scientific (SMLR), Viewray (VRAY), Rockwell Medical (RMTI), Fonar (FONR), Soleno Therapeutics (SLNO), Edap Tms (EDAP), BioSig Technologies (BSGM), Second Sight Medical Products (EYES) and IRIDEX (IRIX).

Based on aggregate information from My MarketBeat watchlists, some companies that other BioLife Solutions investors own include Canopy Growth (CGC), Twilio (TWLO), Cara Therapeutics (CARA), Micron Technology (MU), Progenics Pharmaceuticals (PGNX), AbbVie (ABBV), Amarin (AMRN), Roku (ROKU), Verastem (VSTM) and Alibaba Group (BABA).

BioLife Solutions' stock is owned by a number of of institutional and retail investors. Top institutional shareholders include Roubaix Capital LLC (0.68%), Penbrook Management LLC (0.13%) and Mesirow Financial Investment Management Inc. (0.12%). Company insiders that own BioLife Solutions stock include Andrew G Hinson, Casdin Partners Master Fund, L, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Michael Rice, Raymond W Cohen, Thomas Girschweiler, Todd Berard and Walter Villiger. View Institutional Ownership Trends for BioLife Solutions.

BLFS stock was sold by a variety of institutional investors in the last quarter, including Penbrook Management LLC and Mesirow Financial Investment Management Inc.. Company insiders that have sold BioLife Solutions company stock in the last year include Andrew G Hinson, Greef Roderick De, James Mathers, Johan Wedell-Wedellsborg, Joseph C Schick, Michael Rice, Raymond W Cohen, Todd Berard and Walter Villiger. View Insider Buying and Selling for BioLife Solutions.

BLFS stock was purchased by a variety of institutional investors in the last quarter, including Roubaix Capital LLC. View Insider Buying and Selling for BioLife Solutions.

Shares of BLFS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of BLFS stock can currently be purchased for approximately $16.21.

BioLife Solutions has a market capitalization of $331.49 million and generates $19.74 million in revenue each year. The medical equipment provider earns $3.27 million in net income (profit) each year or $0.14 on an earnings per share basis. BioLife Solutions employs 54 workers across the globe.View Additional Information About BioLife Solutions.

The official website for BioLife Solutions is http://www.biolifesolutions.com/.

BioLife Solutions' mailing address is 3303 MONTE VILLA PARKWAY SUITE 310, BOTHELL WA, 98021. The medical equipment provider can be reached via phone at 425-402-1400 or via email at [email protected]